Heron Therapeutics (HRTX) Proxy Filing summary

Executive summary

• Special Meeting called to approve two proposals related to share issuances exceeding 19.99% of outstanding common stock under Nasdaq Listing Rule 5635(d).

• Proposals involve conversion of convertible senior unsecured promissory notes due 2031 and Series A Convertible Preferred Stock, both held by non-affiliated parties.

• Approval would allow significant increases in outstanding shares, potentially diluting current stockholders' ownership and voting power.

• Failure to approve would require cash repayment of notes or leave preferred stock outstanding, impacting liquidity and capital structure.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock upon conversion of senior unsecured promissory notes, possibly exceeding 19.99% of pre-issuance shares.

• Proposal 2: Approve issuance of common stock upon conversion of Series A Convertible Preferred Stock, possibly exceeding 19.99% of pre-issuance shares.

• Both proposals require majority of votes cast for approval; abstentions and broker non-votes have no effect.

• Board recommends voting FOR both proposals.

Board of directors and corporate governance

• Board is soliciting proxies and will pay all solicitation costs; directors and employees may solicit proxies without additional compensation.

• Board will exercise discretion on any other matters properly brought before the meeting.